Improving Risk Assessment and Early Diagnosis in PAH

Slides:



Advertisements
Similar presentations
Upfront Combination Therapy vs Step-Up Approach for PAH:
Advertisements

Exploring Early Combination Therapy in PAH
Monitoring and Modifying Treatment in PAH
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Starting Strong: Initial Evaluation of the Patient With HCV
Post-autologous Transplant Therapy for Hodgkin Lymphoma
Risk Stratification in PAH: What Do the Latest Data Suggest?
A Paradigm Shift in PAH.
An Update on Oral Prostanoids: Advancing Care for PAH?
The Clinical Enigma of Cardiogenic Shock
Exploring the Spectrum of Excessive Daytime Sleepiness
Identifying and Managing Dyspnea Associated With CTEPH
Setting the Stage – PAH Therapy Trials Current PAH Pharmacotherapies.
UNDERSTANDING RISK STRATIFICATION IN PAH:
Modifying Disease Course in Alzheimer's Disease
The Latest Data on Oral Prostacyclin Therapy in PAH
New Treatments for CTEPH
All About PAH:.
What Would You Do in This Case of MDD?
Follow-Up of the Patient After PE
PAH Therapy Revisited.
Updates in Pulmonary Arterial Hypertension
Treating Vasodilatory Shock in the ICU
Updates in Neuronal Ceroid Lipofuscinosis
Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy
Are We Closer to Personalized Medicine in MS?
WHO Clinical Classification of PH Complex Cases in PH.
Selected Highlights of the Latest Advances in PAH
Your Clinic Your Country
Antithrombotic Protection in CAD and HF
Evolving Science of PAH Treatment
Risk Assessment in PAH.
2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.
Examining the Latest Evidence in PAH
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.
Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea
Navigating Treatment Options in PAH
Preventing Clinical Events in PAH
PAH and Prostacyclin Pathways in Focus
PAH-Related Morbidity as a Predictor of Mortality
Pulmonary Arterial Hypertension and Connective Tissue Disease
Updates in Neuronal Ceroid Lipofuscinosis
What's New in PAH?.
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
Imaging to Assess IPF Progression A Case-Based Approach
Oral Prostacyclin Pathway Agents in PAH
Add-On Therapy to Insulin in T1DM Management
Pulmonary Hypertension Updates From 2018
Incorporating Prostacyclins Into Practice
Program Goals Background: Anticoagulation in Patients With VTE.
Perspective on the Multidisciplinary Management of PAH
Live on PAH: Breathing Life Into Patients With PAH
Patient Stories in PAH: Sequential Therapy in a FC II Patient
Optimal Treatment of PAH
Breaking Barriers in PAH: Role of Novel Early Treatment Strategies
Prostacyclin Pathway Agents in Action
Transitioning Therapy in PAH: Practical Strategies and Considerations
Incorporating New PAH Treatments Into Clinical Practice
PICO model for developing EBM questions
PAH Pathways: What Do the Data Tell Us?”
Binge Eating Disorder.
Clinical Comparisons in CTEPH
Pulmonary Arterial Hypertension and Hospitalizations
Merging the Art and Science of Managing nOH in Clinical Practice
What's New in PAH?.
My PAH Patient.
Treating Pulmonary Embolism Today
Presentation transcript:

Improving Risk Assessment and Early Diagnosis in PAH

Program Themes

Initial Presentation

Initial Presentation (cont)

Physical Exam

Physical Exam (cont)

Physical Exam (cont)

Evaluation of Findings

Test Results: Echo (May 2015)

What Else Can Be Learned From Echo?

Additional Diagnostics

RHC Results

Determinants of Prognosis in PAH

Therapies Based on Risk

Initial Therapy

Clinical Efficacy/Safety AMBITION Trial

Evolving Approach to Combination Therapy

Follow-Up Visit (September 2015)

Echo (March 2016)

RHC Results: Hemodynamics

Clinical Follow-Up + Objective Evaluation

5th World Symposium on PH Goals of Therapy: Setting the Bar Higher

Clinical Efficacy/Safety GRIPHON Trial

GRIPHON: Treatment Effect by Subgroup

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)